Form D · Biotechnology

Black Diamond Therapeutics, Inc.

Cambridge, MA · CIK 0001701541

Offering snapshot reported Dec 6, 2019 · SEC filing

Reported sold
$85M
Offering amount: $85M
Investors reported
28
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 25, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 6, 2019Initial$84,999,941No comparison28SEC filing
Jul 16, 2019Amendment$44,236,469$1,736,496vs Jan 3, 201916SEC filing
Jan 3, 2019Initial$42,499,973No comparison15SEC filing
Aug 22, 2018Initial$5,000,000No comparison1SEC filing
Jan 4, 2018Amendment$12,101,210$5,000,000vs Mar 28, 201711SEC filing
Mar 28, 2017Initial$7,101,210No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-354957

Source: Form D, filed Dec 6, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ali Behbahani Director
Brad Bolzon Director
Bradley Bolzon Director
Elizabeth Buck Executive
David M. Epstein Director, Executive
Brent Hatzis Schoch Executive
Samarth Kulkarni Director
Thomas Leggett Executive
Alexander Mayweg Director
Garry Menzel Director
Fang Ni Executive
Christopher Roberts Executive
Rajeev Shah Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
139 Main Street
Cambridge, MA, 02142